Australian Clinical Labs hits seven-month high on upbeat FY25 outlook

Australian Clinical Labs

29/08/2024 06:59

** Shares of Australian Clinical Labs  ACL.AX  rise as much
as 17.3% to A$3.12 - a seven-month high
    ** Pathology services provider posts FY24 rev of A$696.4 mln
($473.5 mln); forecasts FY25 rev of A$725 mln-A$752 mln
    ** Co posts FY24 underlying EBIT A$62.6 mln; forecasts FY25
underlying EBIT of A$65 mln-A$73 mln
    ** Stock set for best month since Feb. 2023
    ** ACL sees busiest session since mid-July as 2.8 mln shares
exchange hands by 0530 GMT, 2.1x the 30-day avg vol
    ** Stock has fallen 8% so far this year, as of last close

($1 = 1.4699 Australian dollars)

 (Reporting by Sherin Sunny in Bengaluru)
 ((Sherin.Sunny@thomsonreuters.com))